HALO logo

HALO
Halozyme Therapeutics Inc.

4,923
Mkt Cap
$7.72B
Volume
1.52M
52W High
$82.22
52W Low
$47.50
PE Ratio
26.25
HALO Fundamentals
Price
$64.49
Prev Close
$65.40
Open
$64.22
50D MA
$70.01
Beta
0.73
Avg. Volume
1.57M
EPS (Annual)
$2.56
P/B
157.80
Rev/Employee
$3.3M
$10,373.12
Loading...
Loading...
News
all
press releases
Assenagon Asset Management S.A. Takes Position in Halozyme Therapeutics, Inc. $HALO
Assenagon Asset Management S.A. acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Congress Asset Management Co. Cuts Position in Halozyme Therapeutics, Inc. $HALO
Congress Asset Management Co. decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9.4% in the fourth quarter, according to its most recent filing with the Securities...
MarketBeat·10d ago
News Placeholder
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Allworth Financial LP
Allworth Financial LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 322.5% during the third quarter, according to the company in its most recent Form 13F...
MarketBeat·12d ago
News Placeholder
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·14d ago
News Placeholder
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company's royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences...
MarketBeat·16d ago
News Placeholder
Alliancebernstein L.P. Trims Stake in Halozyme Therapeutics, Inc. $HALO
Alliancebernstein L.P. reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 22.3% during the third quarter, according to its most recent 13F filing with the Securities...
MarketBeat·17d ago
News Placeholder
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Clark Capital Management Group Inc.
Clark Capital Management Group Inc. increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.4% in the 3rd quarter, according to the company in its most recent...
MarketBeat·18d ago
News Placeholder
Brevan Howard Capital Management LP Sells 96,806 Shares of Halozyme Therapeutics, Inc. $HALO
Brevan Howard Capital Management LP decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 60.1% during the third quarter, according to the company in its most recent...
MarketBeat·18d ago
News Placeholder
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO
Aquatic Capital Management LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The...
MarketBeat·18d ago
News Placeholder
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Hold" by Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has earned an average rating of "Hold" from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. One...
MarketBeat·20d ago
<
1
2
...
>

Latest HALO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.